Roxana Neyra, MD
Nephrology · Phoenix, AZNPI 1235132895
Payments from drug & device makers
Across 349 payments — averaging $2963.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$309K
- Bard Peripheral Vascular, Inc.$211K
- Bayer$124K
- Akebia Therapeutics Inc$95K
- Vertex$83K
- Cook Research Incorporated$56K
- plus $156K from 24 others
Across 1 payment — averaging $19,691 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$20K
What the payments were for
- Speaking & faculty fees$4,50078%
- Food & beverage$1,23921%
- Education$331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 98 | $308,976 |
| Bard Peripheral Vascular, Inc. | 7 | $211,247 |
| Bayer | 46 | $123,678 |
| Akebia Therapeutics Inc | 99 | $95,144 |
| Vertex | 8 | $83,171 |
| Cook Research Incorporated | 5 | $56,003 |
| Novartis | 11 | $50,824 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $45,821 |
| Ardelyx, Inc. | 18 | $24,765 |
| OPKO Pharmaceuticals, LLC | 3 | $21,901 |
| Novo Nordisk AS | 1 | $7,100 |
| W. L. Gore & Associates, Inc. | 3 | $4,515 |
| AstraZeneca | 20 | $391 |
| Otsuka America Pharmaceutical, Inc. | 5 | $96 |
| Amgen(2 entities) | 5 | $82 |
| Fresenius USA Marketing, Inc. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $38 |
| Venturemed Group, Inc. | 2 | $33 |
| Cormedix Inc. | 1 | $33 |
| GSK | 2 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Leadiant Biosciences, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Merck | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACUSEAL Vascular Graft$4,500
How this compares
$1,034,094 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 124 | $105,425 |
| FarxigaDapagliflozin Propanediol | 89 | $64,683 |
| VelphoroSucroferric Oxyhydroxide | 29 | $58,786 |
| LokelmaSodium Zirconium Cyclosilicate | 68 | $51,655 |
| JardianceEmpagliflozin | 49 | $46,244 |
| OzempicSemaglutide | 33 | $38,273 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $29,051 |
| TrulicityDulaglutide | 17 | $22,174 |
| Lanthanum Carbonate | 28 | $18,469 |
| Sevelamer Carbonate | 111 | $15,684 |
| Eplerenone | 18 | $4,099 |
| Losartan Potassium | 37 | $303 |
| Allopurinol | 49 | $295 |
| Nifedipine ErNifedipine | 22 | $218 |
| Metolazone | 13 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $391 | $116,339157 claims |
| BayerKerendia | $123,678 | $105,425124 claims |
| Fresenius USA Marketing, Inc.Velphoro | $46 | $58,78629 claims |
| Boehringer IngelheimJardiance | $25 | $46,24449 claims |
| Novo NordiskOzempic | $22 | $38,27333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Phoenix
- Leslie ThomasPhoenix$3.1M
- Hasan KhamashPhoenix$1.3M
- Hassan HachemPhoenix$372K
- Sungchun LeePhoenix$341K
- Shouwen WangPhoenix$195K
- Nina PatelPhoenix$174K
- Yuzana ZawPhoenix$159K
- Alexander NimriPhoenix$133K
- Samer Bani HaniPhoenix$99K
- Sandip PatelPhoenix$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.